201 related articles for article (PubMed ID: 33892850)
1. Update in the Mucopolysaccharidoses.
McBride KL; Flanigan KM
Semin Pediatr Neurol; 2021 Apr; 37():100874. PubMed ID: 33892850
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art.
de Castro MJ; Del Toro M; Giugliani R; Couce ML
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502108
[TBL] [Abstract][Full Text] [Related]
3. Newborn screening and diagnosis of mucopolysaccharidoses.
Tomatsu S; Fujii T; Fukushi M; Oguma T; Shimada T; Maeda M; Kida K; Shibata Y; Futatsumori H; Montaño AM; Mason RW; Yamaguchi S; Suzuki Y; Orii T
Mol Genet Metab; 2013; 110(1-2):42-53. PubMed ID: 23860310
[TBL] [Abstract][Full Text] [Related]
4. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.
Lau AA; Hemsley KM
J Mol Med (Berl); 2017 Oct; 95(10):1043-1052. PubMed ID: 28660346
[TBL] [Abstract][Full Text] [Related]
5. Newborn screening of mucopolysaccharidoses: past, present, and future.
Arunkumar N; Langan TJ; Stapleton M; Kubaski F; Mason RW; Singh R; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S
J Hum Genet; 2020 Jul; 65(7):557-567. PubMed ID: 32277174
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for Mucopolysaccharidoses.
Sawamoto K; Chen HH; Alméciga-Díaz CJ; Mason RW; Tomatsu S
Mol Genet Metab; 2018 Feb; 123(2):59-68. PubMed ID: 29295764
[TBL] [Abstract][Full Text] [Related]
7. Treatment of brain disease in the mucopolysaccharidoses.
Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R
Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for mucopolysaccharidosis.
Ponder KP; Haskins ME
Expert Opin Biol Ther; 2007 Sep; 7(9):1333-45. PubMed ID: 17727324
[TBL] [Abstract][Full Text] [Related]
9. Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.
Pan D
Curr Pharm Biotechnol; 2011 Jun; 12(6):884-96. PubMed ID: 21235445
[TBL] [Abstract][Full Text] [Related]
10. Substrate reduction therapies for mucopolysaccharidoses.
Jakóbkiewicz-Banecka J; Piotrowska E; Gabig-Cimińska M; Borysiewicz E; Słomińska-Wojewódzka M; Narajczyk M; Węgrzyn A; Węgrzyn G
Curr Pharm Biotechnol; 2011 Nov; 12(11):1860-5. PubMed ID: 21902626
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology applied to treatment of mucopolysaccharidoses.
Schuh RS; Baldo G; Teixeira HF
Expert Opin Drug Deliv; 2016 Dec; 13(12):1709-1718. PubMed ID: 27322551
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for neurologic manifestations of mucopolysaccharidoses.
Wolf DA; Banerjee S; Hackett PB; Whitley CB; McIvor RS; Low WC
Expert Opin Drug Deliv; 2015 Feb; 12(2):283-96. PubMed ID: 25510418
[TBL] [Abstract][Full Text] [Related]
13. Genome editing in mucopolysaccharidoses and mucolipidoses.
Santos HS; Poletto E; Schuh R; Matte U; Baldo G
Prog Mol Biol Transl Sci; 2021; 182():327-351. PubMed ID: 34175047
[TBL] [Abstract][Full Text] [Related]
14. Novel heparan sulfate assay by using automated high-throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses.
Shimada T; Kelly J; LaMarr WA; van Vlies N; Yasuda E; Mason RW; Mackenzie W; Kubaski F; Giugliani R; Chinen Y; Yamaguchi S; Suzuki Y; Orii KE; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2014; 113(1-2):92-9. PubMed ID: 25092413
[TBL] [Abstract][Full Text] [Related]
15. Gene delivery strategies for the treatment of mucopolysaccharidoses.
Baldo G; Giugliani R; Matte U
Expert Opin Drug Deliv; 2014 Mar; 11(3):449-59. PubMed ID: 24450877
[TBL] [Abstract][Full Text] [Related]
16. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
[TBL] [Abstract][Full Text] [Related]
17. Glycan-based biomarkers for mucopolysaccharidoses.
Lawrence R; Brown JR; Lorey F; Dickson PI; Crawford BE; Esko JD
Mol Genet Metab; 2014 Feb; 111(2):73-83. PubMed ID: 23958290
[TBL] [Abstract][Full Text] [Related]
18. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms.
Shapiro EG; Jones SA; Escolar ML
Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036
[TBL] [Abstract][Full Text] [Related]
19. Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III.
de Ruijter J; de Ru MH; Wagemans T; Ijlst L; Lund AM; Orchard PJ; Schaefer GB; Wijburg FA; van Vlies N
Mol Genet Metab; 2012 Dec; 107(4):705-10. PubMed ID: 23084433
[TBL] [Abstract][Full Text] [Related]
20. Oxidative Stress in Mucopolysaccharidoses: Pharmacological Implications.
Pierzynowska K; Gaffke L; Cyske Z; Węgrzyn G; Buttari B; Profumo E; Saso L
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
